ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 370

Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study (the 1st report of Apple Survey)

Akitomo Okada1, Atsushi Kawakami2, Takaaki Fukuda3, Toshihiko Hidaka4, Tomonori Ishii5, Yukitaka Ueki6, Takao Kodera7, Munetoshi Nakashima8, Yuichi Takahashi9, Seiyo Honda10, Yoshiro Horai2, Tomohiro Koga1, Ryu Watanabe11, Hiroshi Okuno12 and Katsumi Eguchi13, 1Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan, 4Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, 5Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, 6Sasebo Chuo Hospital, Sasebo, Japan, 7Tohoku Kosei Nenkin Hospital, Sendai, Japan, 8Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 9Yu Family Clinic, Sendai, Japan, 10Kurume University School of Medicene, Kurume, Japan, 11Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 12Tohoku University Hospital, Sendai, Japan, 13Sasebo City General Hospital, Sasebo, Nagasaki, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: DMARDs, joint destruction, radiography and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Background/Purpose: There has been few epidemiological report of longitudinal radiographic progression in rheumatoid arthritis (RA) patients captured in daily practice. In 20 related-centers of the Nagasaki University and Tohoku University in Japan we are conducting a large-scale prospective study (Apple Survey) to investigate extent of radiographic progression. We have tried to assess the extent of rapid radiographic progression (RRP) in synthetic disease modifying anti-rheumatic drugs (DMARDs)-treated RA patients.

Methods: We have selected the RA patients treated not by biologic DMARDs but by synthetic DMARDs for 1 year. One hundred fifty-three out of the 964 patients registered between May 09 and March 12 had evaluable data at present. Patients gave their informed consent to be subjected to the protocol that was approved by the Institutional Review Board of Nagasaki University, Tohoku University and related centers. DAS28-ESR was assessed every 3 months. Radiographs of the hands and feet were taken every 6 months. The images were scored by trained readers through modified total Sharp score (mTSS). RRP was defined as yearly progression of mTSS >3.0. We have examined what variables are associated with the development of RRP at 1 year.

Results: Ten variables including gender, disease duration at baseline, age, CRP at baseline (mg/dl), presence of autoantibodies (RF or anti-CCP Abs), DAS28-ESR at baseline, time-integrated DAS28-ESR during 1 year, mTSS at baseline, HAQ at baseline and the use of MTX or non-MTX DMARDs were evaluated through univariate and logistic regression analysis to explore the development of RRP at 1 year. RRP was found in 17 out of 153 patients (11.1%). Logistic regression analysis has found that short disease duration (p = 0.0061), younger age ( p = 0.038), high time-integrated DAS28-ESR ( p = 0.015) and high mTSS at baseline ( p = 0.035) are independent variables to predict the development of RRP. There were the trend of presence of autoantibodies ( p = 0.074) and non-MTX DMARDs use ( p = 0.054) toward RRP at 1 year.

Conclusion: Our results have revealed the characteristic of synthetic DMARDs-treated Japanese RA patients who develop RRP. The treat-to-target strategy is particularly recommended in these patients.


Disclosure:

A. Okada,
None;

A. Kawakami,
None;

T. Fukuda,
None;

T. Hidaka,
None;

T. Ishii,
None;

Y. Ueki,
None;

T. Kodera,
None;

M. Nakashima,
None;

Y. Takahashi,
None;

S. Honda,
None;

Y. Horai,
None;

T. Koga,
None;

R. Watanabe,
None;

H. Okuno,
None;

K. Eguchi,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristic-of-the-japanese-patients-with-rheumatoid-arthritis-ra-of-rapid-radiographic-progression-rrp-treated-with-synthetic-disease-modifying-anti-rheumatic-drugs-dmards-in-daily-practice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology